HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Nonhemolytic passenger lymphocyte syndrome.

AbstractBACKGROUND:
An 8-month-old recipient of a liver segment transplant had anti-D detected for the first time in her Day 5 posttransplant plasma and anti-C detected for the first time in her Day 55 posttransplant plasma. The donor's plasma contained anti-C and anti-D. Clinical and laboratory findings established a diagnosis of passenger lymphocyte syndrome (PLS). Hemolysis did not occur, because the recipient's blood group phenotype was, by chance, D- C-.
STUDY DESIGN AND METHODS:
To evaluate contemporary practice for diagnosing PLS, we conducted a retrospective 10-year literature review.
RESULTS:
There were 31 studies (63 cases) of PLS of which eight cases (four studies) were hematopoietic stem cell and 55 (27 studies) were organ transplants. All eight (100%) hematopoietic stem cell and 52 (95%) organ transplants were associated with hemolysis. Of the four studies of hematopoietic stem cell PLS, three actively screened for posttransplant blood group antibodies. Of 27 studies of organ PLS, one actively screened for antibodies. Antibody screens detected five cases of hematopoietic stem cell PLS before hemolysis was apparent and two cases of organ PLS with antibodies without hemolysis.
CONCLUSION:
Focusing on hemolysis, without a comparable effort to detect donor-derived antibodies diverts from the primary pathophysiology of PLS and limits capturing the full scope of the syndrome. Recognition of hemolytic and nonhemolytic subcategories of PLS is recommended. When feasible, an antibody screen performed on the donor's plasma when collecting the hematopoietic stem cells or before an organ harvest could result in an alert that the donor has formed an alloantibody(s) and the recipient is a risk for PLS. Alternatively, a routine antibody screen performed on the recipient's plasma 1 week posttransplant and, if negative, repeated 3 to 5 weeks posttransplant would detect any donor-derived antibodies and improve alignment of clinical practice with the pathophysiology of PLS.
AuthorsS Gerald Sandler, Suhua Han, Albert Langeberg, Cal Matsumoto, Thomas M Fishbein
JournalTransfusion (Transfusion) Vol. 57 Issue 12 Pg. 2942-2945 (12 2017) ISSN: 1537-2995 [Electronic] United States
PMID29076164 (Publication Type: Case Reports)
Copyright© 2017 AABB.
Chemical References
  • Isoantibodies
  • RHO(D) antibody
  • Rho(D) Immune Globulin
  • anti-c antibody
Topics
  • Blood Group Incompatibility
  • Female
  • Humans
  • Infant
  • Isoantibodies (adverse effects, blood)
  • Liver Transplantation (adverse effects)
  • Lymphocytes (immunology)
  • Rho(D) Immune Globulin (blood)
  • Syndrome
  • Transplant Recipients

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: